Literature DB >> 27285949

Tyrosinemia type II: Novel mutations in TAT in a boy with unusual presentation.

Songul Gokay1, Mustafa Kendirci2, Pembe Soylu Ustkoyuncu2, Fatih Kardas2, Ayse Kacar Bayram3, Hüseyin Per3, Hatice Gamze Poyrazoğlu4.   

Abstract

Tyrosinemia type II is a rare autosomal recessive disorder caused by deficiency of tyrosine aminotransferase (TAT). It may occur with ocular and cutaneous symptoms with or without mental retardation, but epileptic seizure is a rare presentation of this disease. Herein we report the clinical, biochemical and genetic features of a 4-year-old boy who presented with afebrile seizure and photophobia. Genomic DNA was obtained from peripheral blood leukocytes from the whole family. Sequencing analysis was performed using the MiSeq next-generation sequencing platform. Sequencing of TAT indicated two new homozygous mutations p.L312P (c.935T>C) and p.T408M (c.1223C>T) for the proband and his asymptomatic sister. During a 2 year follow-up period, the patient had overall poor compliance with protein-restricted diet, but his asymptomatic sister had good compliance with the diet. Cognitive function of the patient worsened steadily, but his asymptomatic sister maintained normal mental status. Tyrosinemia type II should be considered in the differential diagnosis of children presenting with epileptic seizure and photophobia; furthermore, early diagnosis and protein-restricted regimen are important to reduce the risk of long-term complications of tyrosinemia type II such as mental disability.
© 2016 Japan Pediatric Society.

Entities:  

Keywords:  zzm321990tyrosine aminotransferasezzm321990; cognitive function; epileptic seizure; low-protein diet; tyrosinemia type II

Mesh:

Substances:

Year:  2016        PMID: 27285949     DOI: 10.1111/ped.13062

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  1 in total

1.  Omega-3 fatty acid supplementation can prevent changes in mitochondrial energy metabolism and oxidative stress caused by chronic administration of L-tyrosine in the brain of rats.

Authors:  Milena Carvalho-Silva; Lara M Gomes; Maria L Gomes; Bruna K Ferreira; Patricia F Schuck; Gustavo C Ferreira; Felipe Dal-Pizzol; Jade de Oliveira; Giselli Scaini; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2019-04-04       Impact factor: 3.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.